{"disease":{"id":"moderate-pain","name":"Moderate pain","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"codeine","indication_name":"Mild to Moderate Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Codeine","generic_name":"codeine phosphate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"Opioid analgesic, Antitussive","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dihydrocodeine","indication_name":"Moderate to moderately severe pain relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synalgos-Dc","generic_name":"DIHYDROCODEINE","company_name":"Caraco","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":54,"revenue":null,"mechanism":""},{"drug_id":"meclofenamic-acid","indication_name":"Mild to Moderate Pain Relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meclofenamate","generic_name":"MECLOFENAMIC ACID","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"meclofenamic acid","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"fenoprofen-calcium","indication_name":"Mild to Moderate Pain Relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FENOPROFEN CALCIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"oliceridine","indication_name":"Moderate pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Olinvyk","generic_name":"OLICERIDINE","company_name":"Trevena","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"","quality_score":57,"revenue":null,"mechanism":"Olinvyk works by binding to the mu-type opioid receptor in the brain, which helps to reduce the perception of pain."},{"drug_id":"suzetrigine","indication_name":"moderate to severe acute pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Journavx","generic_name":"SUZETRIGINE","company_name":"Vertex Pharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Sodium Channel Blocker [EPC]","quality_score":65,"revenue":null,"mechanism":"Journavx blocks sodium channels in the nervous system to reduce pain signal transmission."},{"drug_id":"meptazinol","indication_name":"Moderate pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meptamizol","generic_name":"MEPTAZINOL","company_name":"","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"meptazinol","quality_score":26,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02662764","title":"Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":320,"lead_sponsor_name":"Talphera, Inc","has_results":true},{"nct_id":"NCT02603705","title":"Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":281,"lead_sponsor_name":"Egalet Ltd","has_results":false},{"nct_id":"NCT06237231","title":"Efficacy and Safety of DIT112 in the Treatment of Moderate to Severe Pain After Dental Surgery for the Extraction of Impacted Third Molars","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":252,"lead_sponsor_name":"EMS","has_results":false},{"nct_id":"NCT06904248","title":"Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":224,"lead_sponsor_name":"Yangtze River Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT04533243","title":"Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":209,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT04812860","title":"A Study to Evaluate the Efficacy and Safety of HR18042 Tablets in the Treatment of Postoperative Pain of Impacted Tooth.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":187,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06995352","title":"Liposomal Bupivacaine Versus Continuous Peripheral Nerve Blocks for Analgesia Following Ankle Surgery","phase":"PHASE4","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":140,"lead_sponsor_name":"University of California, San Diego","has_results":false},{"nct_id":"NCT06091020","title":"A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Merz Therapeutics GmbH","has_results":false},{"nct_id":"NCT05096494","title":"Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Scilex Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02221674","title":"Use of Tapentadol Oral Solution for Pain After Surgery in Children From Newborn to Less Than 2 Years Old","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"Grünenthal GmbH","has_results":true},{"nct_id":"NCT02680847","title":"Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":32,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07189962","title":"A Pharmacokinetic Study of SHR8554 Injection in the Population With Renal Insufficiency and Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT02101554","title":"Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03225352","title":"A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03802227","title":"A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Nektar Therapeutics","has_results":true}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}